GFPT1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 391 amino acids (332-699 a.a) and having a molecular mass of 43.7kDa.
GFPT1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Glutamine–Fructose-6-Phosphate Transaminase 1 (GFPT1), also known as Glucosamine–Fructose-6-Phosphate Aminotransferase 1, is a crucial enzyme in human metabolism. It plays a significant role in the hexosamine biosynthesis pathway (HBP), which is essential for the production of amino sugars and glycosylation of proteins and lipids .
GFPT1 is the first and rate-limiting enzyme of the hexosamine biosynthesis pathway . It catalyzes the conversion of fructose-6-phosphate and glutamine to glucosamine-6-phosphate and glutamate . This reaction is crucial as it controls the flux of glucose into the hexosamine pathway, which is vital for the synthesis of UDP-N-acetylglucosamine (UDP-GlcNAc), a key substrate for N- and O-linked glycosylation of proteins .
The hexosamine biosynthesis pathway, regulated by GFPT1, is essential for various cellular processes, including protein glycosylation, which affects protein folding, stability, and function . Additionally, GFPT1 has been implicated in the regulation of circadian rhythms by influencing the expression of clock genes such as BMAL1 and CRY1 .
Mutations in the GFPT1 gene have been associated with congenital myasthenic syndromes (CMS), specifically CMS12 and CMS4C . These are genetic disorders characterized by muscle weakness and fatigue due to defects in neuromuscular transmission. Understanding the role of GFPT1 in these conditions can help in developing targeted therapies .